Blood test may help heart failure patients avoid hospital stays
NCT ID NCT04554277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether monitoring a blood marker called sST-2 can help doctors adjust treatment for people with acute heart failure. The goal is to see if this approach reduces hospital readmissions and improves quality of life. Researchers will compare patients whose treatment is guided by sST-2 levels to those receiving usual care over 24 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sST-2 biomarker monitoring
What this could lead to
If successful, this could show that using sST-2 levels to guide treatment reduces hospital readmissions and improves quality of life for heart failure patients.
What could go wrong
This is an early-stage study focused on cost-effectiveness, not a direct treatment. The biomarker may not reliably predict outcomes, and results may not apply to all heart failure patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Pompidou
NOT_YET_RECRUITINGParis, France
Contact Email: •••••@•••••
-
Arnaud de Villeneuve Hospital
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH Béziers
RECRUITINGBéziers, France
Contact Email: •••••@•••••
-
CHU Angers
RECRUITINGAngers, France
Contact Email: •••••@•••••
-
CHU Besançon
RECRUITINGBesançon, France
Contact Email: •••••@•••••
-
CHU Caen
RECRUITINGCaen, France
Contact Email: •••••@•••••
-
CHU Grenoble
RECRUITINGGrenoble, France
Contact Email: •••••@•••••
-
CHU Nimes
RECRUITINGNîmes, France
Contact
-
CHU Rennes
NOT_YET_RECRUITINGRennes, France
Contact Email: •••••@•••••
-
CHU Toulouse
RECRUITINGToulouse, France
Contact Email: •••••@•••••
-
CHU Vannes
RECRUITINGVannes, France
Contact
-
Lapeyronie Hospital
ACTIVE_NOT_RECRUITINGMontpellier, Occitanie, 34295, France